Introduction
GS, moderate-risk disease, prostate cancer
PROSTATE CANCER, PROSTATE
Since the U. S. Preventive Services Task Force (USPSTF) recommended using serum prostate specific antigen (PSA) for prostate cancer (PC) screeningNonsurgical treatment of PC includes active surveillance (AS), androgen deprivation therapy (ADT), radiotherapy (RT), ablative therapy, chemotherapy, and emerging immunotherapy. AS is a therapeutic observation through regular monitoring of serum PSA, DRE results, serial biopsies, and diagnostic imaging (especially prostate magnetic resonance imaging (MRI)). Patients with clinically low-risk PC and some selected patients with moderate-risk disease frequently choose ASThe prognosis of PC patients receiving different treatment modalities varies greatly. Although some patients adopt active surgical treatment, many patients also receive nonsurgical treatment. However, current clinical trials focus more on the prognosis of patients treated with surgery, especially those undergoing radical prostatectomy (RP)The prognosis evaluation of PC in addition to the traditional TNM stage, PSA and Gleason score (GS) is also very important. The nomogram combines various clinicopathological factors, including PSA and GS, to predict cancer-specific survival (CSS) in PC patients, and there are already some nomograms for the prognosis of PC